Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VTVT 
vTv Therapeutics Inc (VTVT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: VTVT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35.5
1 Year Target Price $35.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.42% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.10M USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 2 | Beta 0.67 | 52 Weeks Range 12.62 - 26.99 | Updated Date 10/12/2025 |
52 Weeks Range 12.62 - 26.99 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -150717.64% |
Management Effectiveness
Return on Assets (TTM) -43.93% | Return on Equity (TTM) -209.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34693182 | Price to Sales(TTM) 5064.55 |
Enterprise Value 34693182 | Price to Sales(TTM) 5064.55 | ||
Enterprise Value to Revenue 2040.78 | Enterprise Value to EBITDA -2.11 | Shares Outstanding 2617215 | Shares Floating 1518686 |
Shares Outstanding 2617215 | Shares Floating 1518686 | ||
Percent Insiders 35.51 | Percent Institutions 43.68 |
Upturn AI SWOT
vTv Therapeutics Inc
Company Overview
History and Background
vTv Therapeutics Inc., previously known as High Point Pharmaceuticals, was founded in 2004. It is a clinical-stage biopharmaceutical company focused on developing orally administered treatments for metabolic diseases.
Core Business Areas
- Drug Development: Focuses on the research and development of small molecule drug candidates, primarily targeting metabolic diseases like diabetes and Alzheimer's.
Leadership and Structure
vTv Therapeutics has a board of directors and an executive leadership team. Its leadership is responsible for guiding the company's strategy and operations, particularly in drug development and clinical trials.
Top Products and Market Share
Key Offerings
- TTP399: An orally administered small molecule that is a selective glucokinase activator (GKA) for the treatment of type 1 diabetes (T1D). Competitors include companies developing insulin therapies, glucose monitoring devices, and other diabetes medications. Market share data is not readily available as this product is still under development and not yet generating revenue.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Companies focus on developing new therapies for various diseases, often relying on patent protection to maintain market exclusivity.
Positioning
vTv Therapeutics is a clinical-stage company, meaning it has not yet brought a product to market. Its success depends on the successful development and commercialization of its drug candidates, particularly TTP399. Competitive advantages would include demonstrating superior efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The global diabetes market is estimated to be worth hundreds of billions of dollars. vTv Therapeutics is positioned to capture a portion of this TAM if TTP399 is successfully commercialized and offers a significant advantage over existing diabetes treatments. The total value can be estimated for the Type 1 diabetes market (T1D) as that is what TTP399 targets.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (TTP399) with a unique mechanism of action
- Potential to address unmet needs in diabetes treatment
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on a single lead product candidate
- High risk associated with drug development
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications for TTP399
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- NVO
- SNY
Competitive Landscape
vTv Therapeutics faces strong competition from established pharmaceutical companies with larger resources and approved diabetes treatments. Its advantage hinges on the potential for TTP399 to offer a differentiated treatment option.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily focused on advancing TTP399 through clinical development.
Future Projections: Future growth depends on the success of TTP399 and potential future partnerships, but projections are highly speculative without further information.
Recent Initiatives: Recent initiatives would include progressing TTP399 through clinical trials and seeking potential partnerships.
Summary
vTv Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company focused on developing TTP399 for type 1 diabetes. Its future hinges on the success of its clinical trials, and its small size makes it vulnerable. Positive results could lead to significant gains, while negative results could lead to substantial losses. They need to secure partnerships for funding and face strong competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q), Press Releases, Industry Reports, Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About vTv Therapeutics Inc
Exchange NASDAQ | Headquaters High Point, NC, United States | ||
IPO Launch date 2015-07-30 | CEO, President & Chairman of the Board Mr. Paul J. Sekhri M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://vtvtherapeutics.com |
Full time employees 23 | Website https://vtvtherapeutics.com | ||
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.